Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration

Haq, S. A. ¹ and Sharma, S. K. ²*

¹MVSc in Veterinary Pharmacology and Toxicology, Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana-141004, Punjab, India; ²Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana-141004, Punjab, India

*Correspondence: S. K. Sharma, Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana-141004, Punjab, India. E-mail: sureshksharma@gadvasu.in

(Received 22 Apr 2012; revised version 31 Jul 2013; accepted 13 Aug 2013)

Summary

The pharmacokinetic parameters of ceftazidime, a third generation cephalosporin antimicrobial agent, were investigated in six buffalo calves after single intravenous (IV) and intramuscular (IM) administration at a dose rate of 10 mg/kg body weight. Ceftazidime concentrations in plasma and urine were determined by microbiological assay. Ceftazidime disposition was best fitted by a two-compartmental and a one-compartmental open model with first-order elimination after IV and IM dosing, respectively. After IV administration, distribution was rapid (t½ka = 0.15 ± 0.01 h) with an area under the ceftazidime plasma concentration/time curve (AUC0-∞) of 253.9 ± 7.8 µg/ml.h and a steady state volume of distribution (Vdss) of 45.8 ± 2.7 µg/ml, 0.75 h, 207.9 ± 9.9 µg/ml.h and 81.7 ± 5.9%, respectively. Urinary excretion of ceftazidime was less than 55% 36 h post administration. In vitro plasma protein binding of ceftazidime was 13.1 ± 1.1%. To maintain minimum therapeutic concentration of 4 µg/ml, a satisfactory dosage regimen of ceftazidime in buffalo calves would be 9.4 mg/kg to be repeated at 12 h intervals. In conclusion, ceftazidime (10 mg/kg, IM) shows favorable pharmacokinetic behavior in buffalo calves.

Key words: Buffalo calves, Ceftazidime, Dosage regimen, Pharmacokinetics

Introduction

Ceftazidime is an aminothiazolyl third generation cephalosporin antimicrobial agent. It is active against some susceptible Gram-negative bacilli (Escherichia coli, Proteus spp., Klebsiella spp., Enterobacter spp., Salmonella spp.), Gram-positive pathogens (Staphylococcus spp., Streptococcus spp.) and very active against Pseudomonas aeruginosa (Albarellos et al., 2008). Rational antibiotic therapy requires dosage regimens to be optimized, not only for clinical efficacy, but also to minimize the selection and spread of resistant pathogens. Pharmacokinetic studies of antimicrobial agents, which provide a basis for the determination of satisfactory dosage regimen are relevant when they are undertaken in the species in which the drugs are to be used clinically. Pharmacokinetic data of ceftazidime has been reported in many animal species, including mice (Kita et al., 1992), rats (Matsui et al., 1984; Kita et al., 1992), rabbits (Carbon et al., 1984; Sakata et al., 1984; Kita et al., 1992; Abd-El-Aty et al., 2001), monkeys (Matsui et al., 1984; Kita et al., 1992), calves (Soback and Ziv, 1989), sheep (Rule et al., 1991), cows (Rule et al., 1996), dogs (Matsui et al., 1984; Kita et al., 1992; Moore et al., 2000), cats (Albarellos et al., 2008) and goats (Rule et al., 2011). However, to the best of our knowledge, pharmacokinetic studies in buffalo calves have not been reported. As the usefulness of an antibacterial agent depends on its efficacy, safety and pharmacokinetic disposition in the target animal, the aim of the present study was to investigate the pharmacokinetics of ceftazidime following single intravenous and intramuscular administration in buffalo calves.

Materials and Methods

Six healthy male buffalo calves ranging between 6-12 months of age and weighing between 85-125 kg were used. The animals were housed in an animal shed with concrete floor and adequate ventilation. All animals were clinically healthy before the beginning of the study. Animals were acclimatized under uniform conditions and maintained on green fodder, wheat straw and water ad libitum. They were not under any drug treatment before the study. For the collection of urine, the experimental animals were moved to metabolic stalls of standard size, 12 h before the start of the experiment and kept there for the entire study. The metabolic stalls were designed in such a way that urine voided by animals could be collected at any time interval without any spillage. Before the start of experiment, permission for experiments on these animals was obtained from the Institutional Animal Ethics Committee (IAEC).

The study was performed in two phases, using a cross over design with a washout period of 30 days. Before repeating the drug in the same animals, blood samples...
were collected and assayed for being drug-free. 10% aqueous solutions of ceftazidime-pentahydrate (Glaxo India Limited) were administered by either the intravenous or the intramuscular route at single doses of 10 mg/kg body weight. Animals were randomly assigned to receive intravenous or intramuscular doses first. Intravenous injection of ceftazidime was given into the jugular vein and intramuscular administration was performed in the lower third region of the neck muscles.

Blood samples (4-6 ml) were taken from contra lateral jugular vein into heparinized glass test tubes before administration and at different time intervals viz. 2.5, 5, 10, 15, 30, 45 min and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 h in each group. Plasma from the samples was separated by centrifugation at 2000 g for 15 min and stored at -20°C till analysis, usually the next day. Urine was collected at 4, 8, 12, 16, 20, 24, 28, 32, 36 h after administration of drug. The urine voided by animals was filtered. Its volume was recorded and approximately 5 ml urine sample was stored at -20°C till analysis.

**Determination of ceftazidime concentration**

The concentration of ceftazidime in plasma and urine was estimated by employing the microbiological assay technique (Arret et al., 1971) using E. coli (MTCC 739) as the test organism. Three alternate wells on assay plates were filled with reference concentration (5 µg/ml) and the remaining three with an unknown concentration of drug. Three plates were used for each sample. Plates were incubated at 37°C for a period of 24 h. At the end of incubation, the diameters of zones of inhibition were calculated from the formulae derived for a single and two compartmental open model (Gibaldi and Perrier, 1982).

The plasma concentration time data for each buffalo calves (n=6) after a single intravenous and intramuscular injection (10 mg/kg body weight) was collected and assayed for being drug-free. 10% aqueous solutions of ceftazidime-pentahydrate (Glaxo India Limited) were administered by either the intravenous or the intramuscular route at single doses of 10 mg/kg body weight. Animals were randomly assigned to receive intravenous or intramuscular doses first. Intravenous injection of ceftazidime was given into the jugular vein and intramuscular administration was performed in the lower third region of the neck muscles.

Blood samples (4-6 ml) were taken from contra lateral jugular vein into heparinized glass test tubes before administration and at different time intervals viz. 2.5, 5, 10, 15, 30, 45 min and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 h in each group. Plasma from the samples was separated by centrifugation at 2000 g for 15 min and stored at -20°C till analysis, usually the next day. Urine was collected at 4, 8, 12, 16, 20, 24, 28, 32, 36 h after administration of drug. The urine voided by animals was filtered. Its volume was recorded and approximately 5 ml urine sample was stored at -20°C till analysis.

**Pharmacokinetic analysis**

The plasma concentration time data for each buffalo calf were determined according to the computed least squares regression technique. Two-compartmental and one-compartmental open models were found to be best fit the data, following intravenous and intramuscular administration, respectively. The kinetic parameters were calculated from the formulae derived for a single and two compartmental open model (Gibaldi and Perrier, 1982). The dosage regimen (D) of ceftazidime was also determined based on kinetic data (Baggot, 1977) by using following formulae:

\[ D = C_p \times (\text{min}) \times V_d (\text{c}^{\text{B}}) \]

where,

\[ \text{C}_p \] (min): The minimum therapeutic concentration of ceftazidime

\[ t_1/2 \] : The dosage interval and other parameters are defined in Table 1

**Table 1: Pharmacokinetic parameters of ceftazidime in buffalo calves (n=6) after a single intravenous and intramuscular injection (10 mg/kg body weight)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unit</th>
<th>Route of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_p$</td>
<td>µg/ml</td>
<td>Intravenous Intramuscular</td>
</tr>
<tr>
<td>A</td>
<td>µg/ml</td>
<td>145.6±6.3 45.4±3.2</td>
</tr>
<tr>
<td>B</td>
<td>µg/ml</td>
<td>0.21±0.01 0.24±0.02</td>
</tr>
<tr>
<td>$K_a$</td>
<td>h</td>
<td>4.63±0.4 3.04±0.46</td>
</tr>
<tr>
<td>$t_{1/2a}$</td>
<td>h</td>
<td>0.15±0.01 0.3±0.21</td>
</tr>
<tr>
<td>$t_{1/2β}$</td>
<td>h</td>
<td>3.37±0.28 0.25±0.04</td>
</tr>
<tr>
<td>K12</td>
<td>h</td>
<td>2.32±0.12 6.25±0.12</td>
</tr>
<tr>
<td>$AUC_{0→∞}$</td>
<td>µg/ml.h</td>
<td>1185.4±134.9 1057.8±170.2</td>
</tr>
<tr>
<td>$AUMC_{0→∞}$</td>
<td>µg/ml.h</td>
<td>0.19±0.01 0.23±0.01</td>
</tr>
<tr>
<td>$V_{dss}$</td>
<td>L/kg</td>
<td>0.18±0.01 0.18±0.01</td>
</tr>
<tr>
<td>$Cl_{B}$</td>
<td>ml/kg/h</td>
<td>39.5±1.2 39.2±1.2</td>
</tr>
<tr>
<td>MRT</td>
<td>h</td>
<td>4.63±0.39 4.97±0.57</td>
</tr>
<tr>
<td>F</td>
<td>%</td>
<td>81.7±5.9</td>
</tr>
</tbody>
</table>

Kinetics parameters are as described by Gibaldi and Perrier (1982).

- $C_p$: The expected plasma drug concentration at zero time; A, A' and B: Zero time plasma drug concentration intercept of regression line of absorption, distribution and elimination phase, respectively; $ka$, $α$, and $β$: Hybrid rate constants representing the slopes of absorption, distribution and elimination phases, respectively; $t_{1/2a}$: Absorption half life; $t_{1/2β}$: Distribution half life; $t_{1/2g}$: Elimination half life; $K_a$: Rate constant of drug transfer from central to peripheral compartment and from peripheral to central compartment, respectively; $AUC_{0→∞}$: Total area under the plasma concentration time curve; $AUMC_{0→∞}$: Total area under the first moment curve; $V_{dss}$: Apparent volume of distribution, based on area under the curve; $V_{dss}$: Volume of distribution based on zero time plasma drug concentration intercept of elimination phase; $Cl_{B}$: Total body clearance; MRT: Mean residence time; F: Systemic bioavailability following intramuscular administration

**In vitro plasma protein binding**

**In vitro** binding of ceftazidime to plasma protein was determined by employing the equilibrium dialysis technique (Kunin et al., 1959). The dialyzing bags (4° A pore size), 10 cm long were washed and soaked overnight in distilled water. The various concentrations of ceftazidime e.g. 6.25, 12.5, 25, 50, 100 and 200 µg/ml were prepared in plasma taken from untreated animals. Each dialyzing bag was knotted on one end before filling with 5 ml of plasma containing known amount of drug and the other end was then securely tied. Each bag was immersed in separate tubes containing 5 ml of distilled water and the tubes were incubated at 37°C for 24 h with occasional shaking. At the end of incubation period
water as well as contents of the dialyzing bags were separately analysed for the concentration of ceftazidime. For each concentration, three separate sets of experiments were conducted. The extent of in vitro plasma protein binding of ceftazidime was calculated by the following equation.

\[
\text{Percent of ceftazidime bound to plasma proteins} = \frac{(C_p - C_w)}{C_p} \times 100
\]

where,
- \(C_p\) = Concentration of ceftazidime in plasma after incubation
- \(C_w\) = Concentration of ceftazidime in distilled water after incubation
- \(C_p\) = Concentration of ceftazidime in plasma before incubation

**Results**

Clinical examination of all animals before and after each trial did not reveal any abnormalities. No adverse reactions were observed after a single IV or IM administration of ceftazidime in the animals studied. The mean plasma concentration-time profiles of ceftazidime following IV and IM administrations are presented in Fig. 1. Mean ± SE values of pharmacokinetic parameters estimated from the curve fitting are shown in Table 1. The cumulative percent of total dose excreted in urine (Table 2) after IV and IM administration was 54.0 ± 6.3 and 50.5 ± 2.0%, respectively within 36 h. Taking 8 and 12 h as convenient dosage interval (\(t_1/2\)) and the minimum therapeutic plasma concentration of 0.1, 0.5, 1, 2, 4 and 8 \(\mu\)g/ml and using the values of \(\beta\) and Vd (area) of Table 1, the dosage regimens for ceftazidime were computed in buffalo calves and presented in Table 3.

**Discussion**

In the present study plasma ceftazidime concentration decreased in a bi-exponential manner following intravenous injection, which demonstrates the presence of distribution and elimination phases. Plasma concentration of ceftazidime after IV administration remained greater than MIC (0.25 \(\mu\)g/ml) for 14 h. Ceftazidime shows rapid distribution reflected by the rate constant.

The elimination half life (\(t_1/2\)) of ceftazidime in buffalo calves was longer than reported in unweaned calves (Soback and Ziv, 1989), sheep (Rule et al., 1991), dogs and mice (Kita et al., 1992), lactating and non-lactating cows (Rule et al., 1996), rabbits (Abd-El-Aty et al., 2001) and cats (Albarellos et al., 2008).

The relatively low volume of distribution at steady state in buffalo calves (0.18 ± 0.01 L/kg) was expectable from a beta lactam antibiotic. This value was consistent with that reported in dogs (Matsui et al., 1984) and cats (Albarellos et al., 2008), but was smaller than that reported in unweaned calves (Soback and Ziv, 1989), sheep (Rule et al., 1991) and lactating and non-lactating cows (Rule et al., 1996). The total body clearance (\(Cl_b\)) of ceftazidime in buffalo calves (39.5 ± 1.2 ml/kg/h) was smaller than dogs (Matsui et al., 1984), unweaned calves (Soback and Ziv, 1989), lactating and non-lactating cows (Rule et al., 1996), and cats (Albarellos et al., 2008).

Species differences are relatively common and are frequently related to inter-species variation, assay method used, blood sampling intervals, the health status and the age of the animal, dosing frequency, dose extrapolation, etc.

Ceftazidime plasma disposition curves after IM administration were best fitted by a one-compartmental open model. The plasma concentration-time curve after IM administration documented \(C_{max}\) (45.8 ± 2.7 \(\mu\)g/ml) at 0.75 h, indicating a fast absorption. Plasma drug concentration above minimum therapeutic level (0.25 \(\mu\)g/ml) was detected up to 14 h of administration. The elimination half life (\(t_{1/2b}\)) of ceftazidime after IM (3.01 ± 0.28 h) administration was similar to the half life after IV

---

**Table 3**: Dosage regimen (mg/kg) of ceftazidime to maintain specified plasma ceftazidime concentration in buffalo calves

<table>
<thead>
<tr>
<th>Desired plasma concentration ((\mu)g/ml)</th>
<th>Dosage interval (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>8</td>
</tr>
<tr>
<td>0.5</td>
<td>12</td>
</tr>
<tr>
<td>1</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>2.0</td>
</tr>
<tr>
<td>4</td>
<td>4.0</td>
</tr>
<tr>
<td>8</td>
<td>8.0</td>
</tr>
</tbody>
</table>

**Table 2**: Cumulative percent of ceftazidime excreted in urine of buffalo calves following a single intravenous and intramuscular injection (10 mg/kg body weight)

<table>
<thead>
<tr>
<th>Time interval (h)</th>
<th>Intravenous</th>
<th>Intramuscular</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>25.7 ± 6.6</td>
<td>21.8 ± 2.7</td>
</tr>
<tr>
<td>0-8</td>
<td>43.7 ± 7.1</td>
<td>38.0 ± 3.5</td>
</tr>
<tr>
<td>0-16</td>
<td>47.2 ± 7.2</td>
<td>44.6 ± 2.3</td>
</tr>
<tr>
<td>0-20</td>
<td>51.2 ± 6.6</td>
<td>49.0 ± 2.0</td>
</tr>
<tr>
<td>0-24</td>
<td>52.8 ± 6.5</td>
<td>49.3 ± 1.9</td>
</tr>
<tr>
<td>0-28</td>
<td>53.7 ± 6.3</td>
<td>49.7 ± 1.9</td>
</tr>
<tr>
<td>0-32</td>
<td>53.7 ± 6.3</td>
<td>50.1 ± 2.0</td>
</tr>
<tr>
<td>0-36</td>
<td>53.9 ± 6.3</td>
<td>50.3 ± 2.0</td>
</tr>
</tbody>
</table>

Values given are mean±SE of the results obtained from 3-6 animals.
administration, suggesting that absorption does not interfere with terminal half life.

Bioavailability plays an important role in therapeutic efficacy of a drug. It refers to the percent of drug absorbed from extravascular site of administration to central compartment for pharmacological action. On the basis of area under the plasma concentration-time curve and elimination rate constant of ceftazidime after single intravenous and intramuscular administration in buffalo calves, the bioavailability (81.7 ± 5.9%) was of the order of that reported for rabbits, cows and cats (Rule et al., 1996; Abd-El-Aty et al., 2001; Albarellos et al., 2008), which demonstrates high absorption of drug from the intramuscular injection site. Rapid absorption and high value of bioavailability shows that intramuscular administration of ceftazidime is likely to be as effective as intravenous injection in the treatment of mild to moderate bacterial infections.

Ceftazidime is mostly eliminated by glomerular filtration (Soback and Ziv, 1989; Verhagen et al., 1994; Albarellos et al., 2008). The cumulative percent of total dose excreted in urine within 36 h after IV and IM administration was 54.0 ± 6.3% and 50.5 ± 2.0%, respectively. Incomplete and variant urinary ceftazidime recovery may be explained by several hypotheses: (i) 36-h urine collection was inadequate to collect 100% of the excreted dose, (ii) degradation of ceftazidime in urine and blood may occur either in vivo or in vitro, (iii) ceftazidime may be metabolized, or (iv) the drug may be excreted through an alternate pathway such as bile. Hypothesis (iii) is unlikely because no metabolites of ceftazidime have been identified either by HPLC assay or by bioautography (Harding, 1981). Since fecal ceftazidime concentrations were not measured, it is impossible to rule out biliary excretion as an elimination pathway. Peak urinary level of drug after IV (1154 ± 218 µg/ml) and IM (973 ± 218 µg/ml) administration was detected at 4 h and thereafter remained ≥10 µg/ml in urine up to 36 h post administration. The concentration of ceftazidime in urine of buffalo calves remained higher than the MIC (0.25 to 8 µg/ml) of most microorganisms (Soback and Ziv, 1989; Moore et al., 2000; Casellas et al., 2003; Rhomberg et al., 2004; Albarellos et al., 2008) sensitive to the drug up to 36 h. This suggests that use of ceftazidime in buffalo calves might achieve successful bacterial killing in urinary tract infections caused by microorganisms having susceptibility ≤10 µg/ml.

The extent of protein binding directly affects the pharmacokinetics and therapeutic efficacy of a drug. Pharmacological action depends on the capability of a drug to bind to its target receptors in tissue. At plasma concentration of 6.25 to 200 µg/ml, the extent of plasma protein binding of ceftazidime ranged from 8.8 to 17.9% with a mean ± SE of 13.1 ± 1.1%. Protein binding of ceftazidime in buffalo calves was not concentration dependent. Since these proteins are large molecules, drugs that are bound to proteins cannot pass out of vascular space. Thus, plasma protein binding has the effect of restricting the distribution of drugs. As plasma protein binding increases, the extent of distribution decreases. However, in the present study, other physiochemical properties may permit the extensive penetration into extravascular sites. Further, low plasma protein binding supports the therapeutic effectiveness of ceftazidime in a wide variety of infections because non protein bound antibiotic produces antimicrobial activity.

The main objective of the present study was to determine a satisfactory dosage regimen of ceftazidime in buffalo calves. It is not axiomatic to compute the dosage regimen of ceftazidime to be used effectively in clinical practice for the treatment of mild to severe bacterial infections, without having first conducted a detailed pharmacokinetic study. The MIC values of ceftazidime are 0.25 µg/ml for E. coli, 4 µg/ml for Pseudomonas aeruginosa and 8 µg/ml for Staphylococcus spp. for human and animal strains (Soback and Ziv, 1989; Moore et al., 2000; Casellas et al., 2003; Rhomberg et al., 2004; Albarellos et al., 2008). With minimum therapeutic plasma concentration of ceftazidime as 4.0 µg/ml, the most convenient and suitable dosage regimen of ceftazidime in buffalo calves was 9.4 mg/kg to be repeated at 12 h intervals.

In conclusion, ceftazidime (10 mg/kg, IM) shows favorable pharmacokinetic behavior in buffalo calves, but needs to be evaluated for clinical efficacy and safety in disease conditions in this species before issuing final recommendations. It seems to be a good therapeutic tool for the treatment of most of the infections produced by Gram-negative and Gram-positive susceptible bacteria in buffalo calves. Although, further studies are necessary to examine the MIC values of this agent for important pathogens that affect buffalo calves.

Acknowledgement

The financial assistance provided by Council of Scientific and Industrial Research, New Delhi (India) in the form of research grant (Scheme No.: 37(1395)/10/EMR-II) is gratefully acknowledged.

References


Casellas, JM; Tome, G; Bantar, C; Bertolini, P; Blazquez, N; Borda, N; Couto, E; Cudmani, N; Guerrera, J; Juarez, MJ; Lopez, T; Littvik, A; Mendez, E; Notario, R; Ponce, G; Quinteros, M; Salamone, F; Sparo, M; Sutich, E; Vaylet, S and Wolff, L (2003). Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients. Diagnostic Microbiol. Infect. Dis., 47: 527-537.


مقاله كامل:
فارماکوکینتیک داروي سفتازیديم در گوساله گاوميش
پس از تزریق وریدی و ماهیچاي

شاه احسن حق و سوره كومار شارما

گروه فارماکولوژی و سم شناسی دامپزشکی، دانشگاه علوم دامی و دامپزشکی کروه، دو، لوهیانا. 2014, IJVR, 15, 46, 75-84

پارامترهای فارماکوکینتیکی داروی سفتازیدیم به دنبال تزریق متقرید و ریگید و ماهیچای با دوز 10 mg/kg و ماهیچای با دوز 2 mg/kg مورد ارزیابی قرار گرفته است. در این مطالعه فارمکوکینتیک داروی سفتازیدیم در پلاسمای داروهای رهگیری شده از تزریق وریدی با مدل مایکلیس، یا از تزریق ماهیچای با مدل یک چکشی متغیر احتمالی بوده است. مقدار توزیع (Vd) به دنبال تزریق داروی سفتازیدیم با دوز 10 mg/kg و مقدار Vd به دنبال تزریق ماهیچای با دوز 2 mg/kg برابر با 0.15 ± 0.01 L/kg بوده است. به ترتیب توزیع در گوساله گاومیش 8 ± 7 h و در گوساله گاومیش 11 ± 7 h قرار گرفته است. به علاوه، دوره زنگ خونده (t1/2 β) به دنبال تزریق داروی سفتازیدیم با دوز 10 mg/kg و مقدار (Cmax) به دنبال تزریق ماهیچای با دوز 2 mg/kg برابر با 0.2 ± 0.1 h قرار گرفته است. در این مطالعه، توزیع مدت تکمیلی (T1/2 ka) به دنبال تزریق داروی سفتازیدیم با دوز 10 mg/kg و مدت تکمیلی (T1/2 α) به دنبال تزریق ماهیچای با دوز 2 mg/kg برابر با 9 ± 8 h قرار گرفته است. در کل، توزیع داروی سفتازیدیم در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان مصرف "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است. میزان "AUC0-∞" در گوساله گاومیش 8 ± 7 h در نظر گرفته شده است.